YPSOMED HLDGYY

YPSOMED HLDG

414.5CHFD
+2.0+0.48%
At close at Jun 6, 21:52 GMT
CHF
No trades
See on Supercharts

YPSN fundamentals

Key facts

Market capitalization‪5.65 B‬CHF
Founded2003
Employees (FY)‪2.64 K‬
CEOSimon Michel
About

Ypsomed Holding AG engages in the development and manufacture of injection systems for self-medication of drugs by patients, most notably used to treat diabetes. It operates through the following segments: Ypsomed Diabetes Care, Ypsomed Delivery Systems, and Others. The Ypsomed Diabetes Care segment is involved in the products that are sold directly to hospitals, doctors, pharmacies, and patients via Ypsomed subsidiaries and distributors. The Ypsomed Delivery Systems segment focuses on the pharmaceutical and biotech customers with injection systems and related services. The Others segment consists of Ypsotec and properties not used for operational purposes. The company was founded by Wilhelm Michel on December 29, 2003, and is headquartered in Burgdorf, Switzerland.

Ownership
‪‪13.62 M‬‬
Closely held shares
‪‪9.94 M‬‬ (72.93%)
Free Float shares
‪‪3.69 M‬‬ (27.07%)
Closely held shares
‪‪9.94 M‬‬ (72.93%)
Free Float shares
‪‪3.69 M‬‬ (27.07%)
Capital structure
Market cap
‪‪5.65 B‬‬
Debt
‪‪367.00 M‬‬
Cash & equivalents
‪‪36.49 M‬‬
Enterprise value
‪‪5.98 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪5.65 B‬‬
Price to earning ratio (P/E)
64.36x
Price to sales ratio (P/S)
7.52x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
64.36x
Price to sales ratio (P/S)
7.52x
Valuation ratios
‪0.00‬
‪2.50‬
‪5.00‬
‪7.50‬
‪10.00‬
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪0.00‬
‪20.00‬
‪40.00‬
‪60.00‬
‪80.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪10.0%‬
‪11.1%‬
‪12.2%‬
‪13.3%‬
‪14.4%‬
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪0.00‬
‪‪110.00 M‬‬
‪‪220.00 M‬‬
‪‪330.00 M‬‬
‪‪440.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪110.00 M‬‬
‪‪220.00 M‬‬
‪‪330.00 M‬‬
‪‪440.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪110.00 M‬‬
‪‪220.00 M‬‬
‪‪330.00 M‬‬
‪‪440.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Ypsomed Delivery Systems
Ypsomed Diabetes Care
Other
By country
Period: 2024
Europe
Rest of the World
Switzerland
North America

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
‪0.00‬
‪‪110.00 M‬‬
‪‪220.00 M‬‬
‪‪330.00 M‬‬
‪‪440.00 M‬‬
Actual
Estimate
Earnings
Next:Nov 12, 2025
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
‪0.00‬
‪0.80‬
‪1.60‬
‪2.40‬
‪3.20‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
34.31%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
0.48%
Next payment
2.20
Next ex-date
Jul 4, 2025
Next pay date
Jul 8, 2025
Dividend history
‪0.35%‬
‪0.45%‬
‪0.55%‬
‪0.65%‬
‪0.75%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.60‬
‪1.20‬
‪1.80‬
‪2.40‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪‪−130.00 M‬‬
‪0.00‬
‪‪130.00 M‬‬
‪‪260.00 M‬‬
‪‪390.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪250.00 M‬‬
‪‪500.00 M‬‬
‪‪750.00 M‬‬
‪‪1.00 B‬‬
Assets
Liabilities